Swiss biotech Actelion posted its third-quarter earnings in 2008, revealing artery lung hypertension drug Tracleer as its top seller. Below is the list of the company´s top selling drugs in the first nine months of the year.

Biotech CV Therapeutics posted its third-quarterly 2008 earnings for Ranexa, its only marketed drug. Below, Ranexa sales in the first nine months of this year.

Cephalon Inc reported a third-quarter profit that missed analyst expectations, but its new cancer drug Treanda continued an impressive launch, and raised its full-year earnings forecast.

Cephalon Inc posted its third-quarter earnings, with insomnia drug Provigil taking top place. Below is a list of the biotech company’s sales for the first nine months of the year.

Massachusetts-based Sepracor Inc posted its third-quarter earnings for 2008, with insomnia drug Lunesta taking top place. The list of drugs and their sales for the first nine months of this year can be seen below.

Sepracor Inc posted a sharp decline in third-quarter profit, as lower reimbursement rates from Medicare hurt sales of its asthma drug Xopenex.

Celgene has presented its Q3 2008 financial results, featuring the multiple myeloma drugs Revlimid and Thalomid as the company´s key revenue drivers. First nine months results.

U.S biotech Celgene Corp posted third-quarter profit that more than tripled on a 69 percent rise in revenues. Most of the company´s revenue growth came from its top-selling bone-marrow cancer drug Revlimid. Further Details.

Biotech giant Genzyme posted its 3Q 2008 financial results. Genzyme´s blockbuster Cerezyme and its phosphorus drug Renagel lead tops list of its most widely sold drugs. Full information of first nine months results 2008

California-based biotech Amgen Inc posted its third-quarter 2008 earnings, with Enbrel (rheumatoid arthritis & others) taking top-place. Below a full list of the company´s best selling drugs in the first nine months of this year.

The world´s largest biotechnology company, Amgen Inc, reported their third quarter profits rose more than five times, as sales of its drugs for anemia (Aranesp, Epogen), cancer and arthritis (Enbrel) increased.

U.S. biotech Biogen Idec posted its third-quarterly earnings for 2008, in which its multiple sclerosis drug Avonex showed a rise in sales, as well as Tysabri, for the same condition. Below is the list of Biogen´s best sellers in the first nine months of this year.

Biogen Idec Inc posted third-quarter earnings that topped expectations, but sales of its multiple sclerosis drug Tysabri have slowed, its growth rate dropping 18 percent in the third quarter from the 25 percent in the second quarter, sending the company´s shares down as much as 4.6 percent.

Californian biotech Gilead Sciences Inc posted its third quarter 2008 earnings, revealing its HIV drugs´ sales rose sharply, especially the newer Atripla, the earnings of which increased 77 percent compared to the same period last year. Below is the listing of Gilead´s top sellers in the third quarter.

Gilead Sciences Inc reported a 27 percent increase in third-quarter profit, driven by increased sales of its HIV drugs Truvada, Atripla and Viread, while revenue rose 30 percent compared to last year. Further details.

California-based Genentech Inc posted its third quarter 2008 earnings, in which cancer drug Avastin took top place. Below are listed the biotech company´s best selling drugs during the first nine months of the year.

U.S. biotech Genentech Inc reported a rise in profits of 6.7 percent in its third quarter posting, with sales above $ 2.45 billion dollars. Further details.

U.S. biotech Onyx Pharma, together with partner Bayer HealthCare Pharmaceuticals, Inc. posted their cancer drug Nexavar global net sales for the year´s second quarter.

Massachusetts-based biotech company Sepracor presented its Q2 2008 financial results. The new generation sleeping pill Lunesta tops the list of most widely prescribed Sepracor drugs. In-depth information on the biotech firm’s first semester results.

California-based biotech Amgen posted its second-quarterly 2008 earnings, revealing white blood cells booster Neulasta gained first place. Listed are the details of the top selling products in Q2 2008.